LONDON, UK: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that Sir Nigel Rudd will be returning as Company Chairman, effective immediately. Sir Nigel has an impressive track record in creating value for shareholders in a variety of…